BEAM versus pharmacokinetics‐directed BuCyVP16 conditioning for patients with peripheral T‐cell lymphoma undergoing high‐dose therapy with autologous hematopoietic cell transplantation-Reference-Cited by-同舟云学术

BEAM versus pharmacokinetics‐directed BuCyVP16 conditioning for patients with peripheral T‐cell lymphoma undergoing high‐dose therapy with autologous hematopoietic cell transplantation

Published:2024-03-25 Issue:6 Volume:99 Page:1180-1183
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Stuver Robert¹^ORCID,Mian Agrima²,Brown Samantha³^ORCID,Devlin Sean³,Caimi Paolo F.²,Chinapen Stephanie⁴^ORCID,Dahi Parastoo⁴⁵,Dean Robert²,Epstein‐Peterson Zachary D.¹,Hill Brian²,Horwitz Steven M.¹⁵,Lahoud Oscar¹⁴⁵^ORCID,Lin Richard⁴⁵,Moskowitz Alison J.¹,Sauter Craig²,Shah Gunjan⁴⁵,Winter Alison²^ORCID,Jagadeesh Deepa²,Scordo Michael⁴⁵

Affiliation:

1. Department of Medicine, Lymphoma Service Memorial Sloan Kettering Cancer Center New York New York USA

2. Department of Hematology and Medical Oncology Taussig Cancer Center, Cleveland Clinic Cleveland Ohio USA

3. Department of Epidemiology & Biostatistics Memorial Sloan Kettering Cancer Center New York New York USA

4. Department of Medicine, Adult Bone Marrow Transplant Service Memorial Sloan Kettering Cancer Center New York New York USA

5. Department of Medicine, Cellular Therapy Service Memorial Sloan Kettering Cancer Center New York New York USA

Funder

National Institutes of Health

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27291

Reference6 articles.

1. International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

2. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study

3. Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

4. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma

5. BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin’s lymphomas